| |
Geron Corporation (GERN)
|
| Last Traded At: |
$4.89
+
$0.05
|
| Volume: |
642,033 |
| Price/Earnings: |
$0.00 |
| Earnings Per Share: |
($0.73) |
| 52 Week High: |
$7.51 |
| 52 Week Low: |
$4.37 |
 |
| StockSpiker Coverage & Performance |
|
This stock has been covered by StockSpiker on the following dates. In addition, the percentage change from the coverage date and today's price is shown.
|
| Coverage |
Coverage
Date |
Gain Since Then |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| About Geron Corporation |
| Geron is developing first-in-class biopharmaceuticals for the treatment of
cancer and chronic degenerative diseases, including spinal cord injury, heart
failure and diabetes. We are advancing telomerase targeted therapies, including
an anti-cancer drug and a cancer vaccine, through multiple clinical trials. We
are also the world leader in the development of human embryonic stem cell-based
therapeutics, with our spinal cord injury treatment anticipated to be the first
such product to enter clinical development.
We were incorporated in 1990 under the laws of Delaware. Our principal
executive offices are located at 230 Constitution Drive, Menlo Park, California
94025. Our telephone number is (650) 473-7700. |
 |
|
This website is intended to provide information only. If you are seeking advice on any matters relating to information on this website, you should - where appropriate - contact your broker or investment manager directly with your specific questions or seek advice from qualified Professional Financial advisor.
Whether you are a technical daytrader, or a long term fundamental investor, the StockSpiker gives you investment ideas based on the most relevant recent price
history of stocks. Here are some recent movers that we have reported on:
|
| |